Related Experiment Video
Updated: May 31, 2026
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
A novel approach to percutaneous right-ventricular mechanical support
Hiroo Takayama1, Yoshifumi Naka, Susheel K Kodali
1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY 10032, USA.
Summary
This study shows the percutaneous CentriMag right-ventricular assist device (RVAD) is a feasible option for hemodynamic support. The device improved patient vitals and oxygen saturation, offering a potential alternative for cardiac care.
Area of Science:
- Cardiology
- Medical Devices
- Cardiovascular Surgery
Background:
- Right-ventricular assist devices (RVADs) are crucial for managing right heart failure.
- Percutaneous approaches offer potential advantages in VAD implantation and management.
- The CentriMag system represents a novel platform for temporary mechanical circulatory support.
Purpose of the Study:
- To evaluate the initial clinical experience and feasibility of a newly developed percutaneous CentriMag right-ventricular assist device (perc CM-RVAD).
- To assess the hemodynamic effects and patient outcomes associated with the perc CM-RVAD.
- To explore the role of perc CM-RVAD in providing temporary circulatory support and bridging to other therapies.
Main Methods:
- The perc CM-RVAD utilized flexible inflow (femoral vein to right atrium) and outflow (right internal jugular vein to pulmonary artery) cannulas.
- Biventricular support was achieved using a left VAD (LVAD) when necessary, via percutaneous or fully implantable configurations.
- Eight patients underwent successful implantation of the perc CM-RVAD between January 2009 and June 2010.
Main Results:
- Successful implantation was achieved in all eight patients.
- Hemodynamic parameters including mean blood pressure, heart rate, and central venous pressure showed improvement.
- Mixed venous oxygen saturation (SvO2) significantly increased from 64 ± 20 Torr to 78 ± 6 Torr (P < 0.01).
- Seven patients had the device explanted after myocardial recovery; three were bridged to other devices (including one to a surgical BiVAD).
- One patient experienced mortality due to multiple-organ failure post-explantation.
Conclusions:
- The percutaneous CentriMag right-ventricular assist device (perc CM-RVAD) demonstrated feasibility in initial use.
- The device provided significant hemodynamic improvement in patients with right heart dysfunction.
- Perc CM-RVAD serves as a viable temporary support option and bridge to recovery or other advanced therapies.
